Transformative Biotech was featured in GenomeWeb on April 17, 2026, in an article highlighting the company’s DirectAmp™ extraction-free PCR buffer chemistry and its potential to transform point-of-care infectious disease testing.
“We’re removing one of the biggest bottlenecks in molecular testing — the extraction step,” said CEO Kevin Kraus. “PCR can really finally operate at the speed, cost, and scale that patients actually need.”
The article covers the technology’s real-world validation across nearly 600,000 patient samples, its origins at the University of Colorado Anschutz, and the company’s plans to raise $6 million to advance buffer commercialization and support studies needed to file for 510(k) clearance. The company is also developing the @ANYWHERE™ handheld testing device as a longer-term initiative.
Read the full article at GenomeWeb.com (subscription may be required).
